SCHEMBL4969576

SCHEMBL4969576

c1cc2cc-2c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL475971 0.95 MEN1 (0.56)
Iodide SCHEMBL27407990 0.95
Water SCHEMBL27620318 0.95
Ammonia Solution, Strong SCHEMBL2325144 0.95
Methane SCHEMBL17800724 0.95
Phosphine SCHEMBL27544257 0.95
Hydrogen Sulfide SCHEMBL3569701 0.95
SCHEMBL31290738 0.95 MEN1 (0.65)
Hydrazine SCHEMBL10481629 0.91
Ethane SCHEMBL28709478 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882754-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-10-03 EP disclosed
WO-2011150288-A1 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2011-12-01 WO disclosed
EP-1558730-B1 INHIBITOR-RESISTANT HCV NS3 PROTEASE BOEHRINGER INGELHEIM INT (DE) 2008-01-30 EP disclosed
US-7208309-B2 Comprises amino acid sequence mutated in the substrate binding pocket; useful in screening compounds having therapeutic value against drug resistant strains BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-24 US disclosed
EP-1558730-A1 INHIBITOR-RESISTANT HCV NS3 PROTEASE Boehringer Ingelheim International GmbH (DE) 2005-08-03 EP disclosed
US-20050019753-A1 Comprises amino acid sequence mutated in the substrate binding pocket; useful in screening compounds having therapeutic value against drug resistant strains BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-27 US disclosed
WO-2004039970-A1 INHIBITOR-RESISTANT HCV NS3 PROTEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-05-13 WO disclosed